Investigating the Impact of Momelotinib on Myelofibrosis Patients: A Poster from ASH

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mary Frances McMullin, MD The MOMENTUM study evaluated the impact of the treatment option momelotinib on patient-reported outcomes, including symptom burden and overall quality of life. Joining Dr. Charles Turck to share the key findings and potential implications for myelofibrosis care is Dr. Mary Francis McMullin, who co-authored and presented the poster at the American Society of Hematology (ASH) Annual Meeting and Exposition.